Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: Preliminary data

Journal of the American Academy of Dermatology

Volumn 62, Issue 6, 2010, Pages

  Paradisi, Andrea ^a   Caldarola, Giacomo ^a   Capizzi, Rodolfo ^a   Siciliano, Massimo ^a   Annichiarico, Eleonora ^a   Vecchio, Fabio Maria ^a   Amerio, Pier Luigi ^a   De Simone, Clara ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA2A INTERFERON; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; GALACTOSYLTRANSFERASE; INFLIXIMAB; PSORALEN; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEPATITIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; KIDNEY DYSFUNCTION; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VIRUS LOAD;

EID: 77951893304     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.07.010     Document Type: Article

References (5)

1. Carlin C.S., Feldman S.R., Krueger J.G., Menter A., and Krueger G.G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 50 (2004) 859-866
2. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
3. Peterson J.R., Hsu F.C., Simkin P.A., and Wener M.H. Effect of tumour necrosis factor a antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62 (2003) 1078-1082
4. Magliocco M.A., and Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and cocncurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 (2004) 580-584
5. Marotte H., Fontanges E., Bailly F., Zoulim F., Trepo C., and Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 46 (2007) 97-99